Gensaic and Novo Nordisk Forge $354M Partnership to Advance Precision Therapies

Cambridge, MA, March 3, 2025 (Business Wire) -- Gensaic and Novo Nordisk have formed a collaboration worth up to $354 million per target to develop precision therapies. The partnership integrates Gensaic’s AI-driven ligand discovery with Novo Nordisk’s drug development expertise. The goal is to create innovative treatments for cardiometabolic diseases using targeted intracellular delivery.

Read full article here.